Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.34 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.34 |
| ▸ | MMP9 | P14780 | 3/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 3/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 2/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7862190 | 1.00 | S1PR5 (0.37) | S1PR5PPARGPPARAS1PR1MMP2 | |
| SCHEMBL6695546 | 0.81 | P2RX3 (0.38) | EGLN1P2RX3MMP13 | |
| SCHEMBL6694306 | 0.75 | S1PR5 (0.36) | S1PR5PPARGPPARAS1PR1MMP2 | |
| SCHEMBL6693849 | 0.75 | S1PR5 (0.44) | S1PR5PPARGPPARAMMP2MMP9 | |
| SCHEMBL6690308 | 0.70 | S1PR5 (0.40) | S1PR5PPARGPPARAMMP2MMP9 | |
| SCHEMBL6691197 | 0.62 | MMP1 (0.45) | S1PR5MMP2MMP9FAAHEGLN1 | |
| SCHEMBL9157209 | 0.62 | LTA4H (0.52) | S1PR5LTA4HEPHX2 | |
| SCHEMBL6694975 | 0.61 | MMP2 (0.46) | PPARGPPARAS1PR1MMP2MMP9 | |
| SCHEMBL6441891 | 0.60 | SRD5A2 (0.62) | S1PR5PPARGPPARALTA4HEPHX2 | |
| SCHEMBL2171661 | 0.60 | FFAR1 (0.53) | S1PR5PPARGPPARALTA4HEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | claimed |
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | ROBINSON RALPH P (US) | 2002-10-10 | — | — | US | claimed |
| US-6458822-B2 | (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES | PFIZER INC. | 2002-10-01 | — | — | US | claimed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | ROBINSON RALPH P (US) | 2002-10-10 | — | — | US | disclosed |
| US-6458822-B2 | (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES | PFIZER INC. | 2002-10-01 | — | — | US | disclosed |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | PFIZER PRODUCTS INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | MMP1, MMP8, MMP13 | S1PR5 691/4885PPARG 1856/4885PPARA 3044/4885 |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | MMP1, MMP8, MMP13 | S1PR5 691/4885PPARG 1856/4885PPARA 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.